Cellebration’s stem cell technology isolates a maximum number of autologous (your own) or allogeneic (others) stem cells. Treatment is implemented in the targeted area where the cells can colonize in the damaged area, adapt the properties of resident stem cells, and initiate lost function that has occurred as an outcome of the disease.
Current data suggest evidence of differentiation of stem cells into dopamine producing neurons.
These cells are administered through one of two methods after a considerable analysis of the patient’s unique history.
Intrathecal Administration
In this delivery mode, cells are infused in the cerebrospinal fluid through the subarachnoid spaces of the spinal canal.
Intravenous Administration
In this delivery mode, cells are infused into the peripheral veins to expand blood volumes in the system, to ensure the maximum number of cells are reaching the targeted area.
Infused back into the body, these cells can be repopulated at the damaged parts of the brain. Through paracrine effects, they can differentiate into neurons or other damaged cells to improve functions of the brain. With this approach, it is now possible to obtain notable improvements for patients with Parkinson’s disease to reduce symptoms and improve functional abilities.